84年鼠女哪年财运最旺,857comvvv色九欧美激情|85PO_87国产精品欲av国产av资源

[1]徐武,程利華,張禮平,等.紫車散外敷聯(lián)合塞來昔布膠囊口服治療濕熱瘀閉型膝關(guān)節(jié)滑膜炎的臨床研究[J].中醫(yī)正骨,2017,29(10):30-34.
　XU Wu,CHENG Lihua,ZHANG Liping,et al.Clinical study on external application of Ziche San(紫車散)combined with oral application of celecoxib capsules for treatment of gonarthromeningitis with syndrome of BLOCKADE of DAMP-HEAT and STATIC BLOOD[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(10):30-34.
點(diǎn)擊復(fù)制

紫車散外敷聯(lián)合塞來昔布膠囊口服治療濕熱瘀閉型膝關(guān)節(jié)滑膜炎的臨床研究()
分享到：

《中醫(yī)正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第29卷
期數(shù):
2017年10期
頁碼:
30-34
欄目:
臨床研究
出版日期:
2017-10-20

文章信息/Info

Title:
Clinical study on external application of Ziche San(紫車散)combined with oral application of celecoxib capsules for treatment of gonarthromeningitis with syndrome of BLOCKADE of DAMP-HEAT and STATIC BLOOD
作者:
徐武1; 程利華1; 張禮平2; 秦鵬俊3; 劉德玉4; 朱立國5
1.陜西中醫(yī)藥大學(xué),陜西 咸陽 712046; 2.陜西中醫(yī)藥大學(xué)第二附屬醫(yī)院,陜西 咸陽 712000; 3.陜西省商洛市中醫(yī)醫(yī)院,陜西 商洛 726000; 4.陜西中醫(yī)藥大學(xué)附屬醫(yī)院,陜西 咸陽 712046; 5.中國中醫(yī)科學(xué)院望京醫(yī)院,北京 100102
Author(s):
XU Wu1; CHENG Lihua1; ZHANG Liping2; QIN Pengjun3; LIU Deyu4; ZHU Liguo5
1.Shanxi University of Chinese Medicine,Xianyang 712046,Shanxi,China 2.The Second Affiliated Hospital of Shanxi University of Chinese Medicine,Xianyang 712000,Shanxi,China 3.Shangluo Hospital of Traditional Chinese Medicine,Shangluo 726000,Shanxi,China 4.The Affiliated Hospital of Shanxi University of Chinese Medicine,Xianyang 712046,Shanxi,China 5.Wangjing Hospital of China Academy of Chinese Medical Sciences,Beijing 100102,China
關(guān)鍵詞:
滑膜炎;  膝關(guān)節(jié);  紫車散;  塞來昔布膠囊;  濕熱瘀閉;  臨床試驗(yàn)
Keywords:
Key words synovitis;  knee joint;  Ziche San;  Celecoxib capsules;  syndrome of blockade of damp-heat and static blood;  clinical trail
摘要:
目的:觀察紫車散外敷聯(lián)合塞來昔布膠囊口服治療濕熱瘀閉型膝關(guān)節(jié)滑膜炎的臨床療效和安全性。方法:將63例符合要求的濕熱瘀閉型膝關(guān)節(jié)滑膜炎患者隨機(jī)分為2組,聯(lián)合治療組28例、塞來昔布組35例。聯(lián)合治療組采用紫車散外敷聯(lián)合塞來昔布膠囊口服治療,塞來昔布組單純采用塞來昔布膠囊口服治療,共治療4周。分別于治療前和治療結(jié)束后測定患者的紅細(xì)胞沉降率(erythrocyte sedimentation rate,ESR)、超敏C反應(yīng)蛋白(hypersensitive C-reactive protein,hs-CRP)水平、膝關(guān)節(jié)疼痛視覺模擬量表(visual analogue scale,VAS)評分及Lysholm膝關(guān)節(jié)評分,觀察患者治療期間的并發(fā)癥發(fā)生情況。結(jié)果:治療前2組患者的ESR比較,差異無統(tǒng)計(jì)學(xué)意義(t=0.077,P=0.567); 治療結(jié)束后2組患者的ESR均降低[(36.04±11.04)mm·h-1,(11.61±6.30)mm·h-1,t=13.818,P=0.000;(34.37±11.02)mm·h-1,(17.23±7.45)mm·h-1,t=10.411,P=0.000],聯(lián)合治療組的ESR低于塞來昔布組(t=1.480,P=0.002)。治療前2組患者的hs-CRP水平比較,差異無統(tǒng)計(jì)學(xué)意義(t=0.201,P=0.691); 治療結(jié)束后2組患者的hs-CRP水平均降低[(40.57±11.73)mg·L-1,(7.39±2.31)mg·L-1,t=15.599,P=0.000;(39.37±11.96)mg·L-1,(16.91±6.68)mg·L-1,t=9.936,P=0.000],聯(lián)合治療組的hs-CRP水平低于塞來昔布組(t=26.264,P=0.000)。治療前2組患者的膝關(guān)節(jié)疼痛VAS評分比較,差異無統(tǒng)計(jì)學(xué)意義(t=0.129,P=0.657); 治療結(jié)束后2組患者的VAS評分均降低[(6.54±1.62)分,(1.93±0.22)分,t=10.827,P=0.000;(6.71±1.55)分,(2.74±0.60)分,t=13.398,P=0.000],聯(lián)合治療組的VAS評分低于塞來昔布組(t=2.333,P=0.029)。治療前2組患者的Lysholm膝關(guān)節(jié)評分比較,差異無統(tǒng)計(jì)學(xué)意義(t=0.306,P=0.826); 治療結(jié)束后2組患者的Lysholm評分均增大[(54.04±12.56)分,(82.36±7.99)分,t=-8.908,P=0.000;(54.71±11.78)分,(74.69±9.11)分,t=-10.128,P=0.000],聯(lián)合治療組的Lysholm評分大于塞來昔布組(t=0.613,P=0.001)。2組患者治療期間血、尿、大便常規(guī)檢查,肝腎功能檢查及心電圖檢查均未見異常,均未出現(xiàn)皮膚過敏癥狀。結(jié)論:紫車散外敷聯(lián)合塞來昔布膠囊口服,能有效抑制濕熱瘀閉型滑膜炎患者的炎癥反應(yīng)、減輕膝關(guān)節(jié)疼痛、改善膝關(guān)節(jié)功能,療效優(yōu)于單純口服塞來昔布,而且具有較高的安全性。
Abstract:
ABSTRACT Objective:To observe the clinical curative effects and safety of external application of Ziche San(紫車散,ZCS)combined with oral application of celecoxib capsules for treatment of gonarthromeningitis with syndrome of BLOCKADE of DAMP-HEAT and STATIC BLOOD(濕熱瘀閉,BDHSB).Methods:Sixty-three patients with BDHSB-type gonarthromeningitis were enrolled in the study andwere randomly divided into 2 groups,28 cases in combination therapy group and 35 cases in celecoxib group.The patients in combination therapy group were treated with external application of ZCS combined with oral application of celecoxib capsules,while the patients in celecoxib group were treated with monotherapy of oral application of celecoxib capsules for consecutive 4 weeks.Erythrocyte sedimentation rates(ESR),hypersensitive C-reactive protein(hs-CRP)levels,knee pain visual analogue scale(VAS)scores and Lysholm knee scores were measured and compared between the 2 groups before treatment and after the end of the treatment respectively,and the complication rates were observed during the treatment period.Results:There was no statistical difference in ESR between the 2 groups before the treatment(t=0.077,P=0.567).The ESR decreased in both of the 2 groups after the end of the treatment(36.04+/-11.04 vs 11.61+/-6.30 mm/h,t=13.818,P=0.000; 34.37+/-11.02 vs 17.23+/-7.45 mm/h,t=10.411,P=0.000),and the ESR were lower in combination therapy group compared to celecoxib group(t=1.480,P=0.002).There was no statistical difference in hs-CRP levels between the 2 groups before the treatment(t=0.201,P=0.691).The hs-CRP levels decreased in both of the 2 groups after the end of the treatment(40.57+/-11.73 vs 7.39+/-2.31 mg/l,t=15.599,P=0.000; 39.37+/-11.96 vs 16.91+/-6.68 mg/l,t=9.936,P=0.000),and the hs-CRP levels were lower in combination therapy group compared to celecoxib group(t=26.264,P=0.000).There was no statistical difference in knee pain VAS scores between the 2 groups before the treatment(t=0.129,P=0.657).The VAS scores decreased in both of the 2 groups after the end of the treatment(6.54+/-1.62 vs 1.93+/-0.22 points,t=10.827,P=0.000; 6.71+/-1.55 vs 2.74+/-0.60 points,t=13.398,P=0.000),and the VAS scores were lower in combination therapy group compared to celecoxib group(t=2.333,P=0.029).There was no statistical difference in Lysholm knee scores between the 2 groups before the treatment(t=0.306,P=0.826).The Lysholm knee scores increased in both of the 2 groups after the end of the treatment(54.04+/-12.56 vs 82.36+/-7.99 points,t=-8.908,P=0.000; 54.71+/-11.78 vs 74.69+/-9.11 points,t=-10.128,P=0.000),and the Lysholm knee scores were higher in combination therapy group compared to celecoxib group(t=0.613,P=0.001).The routine examination results of blood,urine,stool,hepatorenal function and electrocardiography were normal and no skin allergy symptom was found in both of the 2 groups during the treatment period.Conclusion:The combination therapy of external application of ZCS and oral application of celecoxib capsules can effectively inhibit the inflammatory reaction,relieve the knee pain and improve the knee function in patients with BDHSB-type gonarthromeningitis,and its curative effect is better than that of monotherapy of oral application of celecoxib capsules,meanwhile,it has high safety.

參考文獻(xiàn)/References:

[1] 喬登朝,王少華,白玉,等.塞來昔布聯(lián)合三七消腫止痛散治療創(chuàng)傷性膝關(guān)節(jié)滑膜炎臨床觀察[J].風(fēng)濕病與關(guān)節(jié)炎,2017,6(4):25-28.
[2] BILTHARIYA U,JAIN N,RAJORIYA V,et al.Folate-conjugated albumin nanoparticles for rheumatoid arthritis-targeted delivery of etoricoxib[J].Drug Dev Ind Pharm,2015,41(1):95-104.
[3] 吳震,童培建,張培祥,等.張氏膝痛方聯(lián)合塞來昔布膠囊口服治療濕熱阻絡(luò)型膝關(guān)節(jié)滑膜炎的臨床研究[J].中醫(yī)正骨,2017,29(4):13-15.
[4] BHOSALE UA,QURAISHI N,YEGNANARAYAN R,et al.A cohort study to evaluate cardiovascular risk of selective and nonselective cyclooxygenase inhibitors(COX-Is)in arthritic patients attending orthopedic department of a tertiary care hospital[J].Niger Med J,2014,55(5):417-422.
[5] 賈麗芳.中西醫(yī)結(jié)合治療膝關(guān)節(jié)滑膜炎的研究新進(jìn)展[J].北方藥學(xué),2013,10(3):49-50.
[6] 國家中醫(yī)藥管理局.中醫(yī)病證診斷療效標(biāo)準(zhǔn)[M].南京:南京大學(xué)出版社,1994:197.
[7] LYSHOLM J,GILLQUIST J.Evaluation of knee ligament surgery results with special emphasis on use of a scoring scale[J].Am J Sports Med,1982,10(3):150-154.
[8] 吳歡,占遠(yuǎn),陳海芳.UHPLC-ESI-Q-TOF-MS/MS對紫花地丁中化學(xué)成分的快速表征[J].中國實(shí)驗(yàn)方劑學(xué)雜志,2016,22(24):70-75.
[9] 宋妍.紫花地丁苗理作用的研究現(xiàn)狀[J].中醫(yī)臨床研究,2017,9(12):136-137.
[10] 王芳芳,潘競先,歐陽飚.基于分子對接的車前草抗炎機(jī)制研究[J].中醫(yī)藥學(xué)報(bào),2012,40(2):78-81.
[11] 李永生,何希瑞,楊燕,等.紫花地丁化學(xué)成分與藥理活性研究新進(jìn)展[J].環(huán)球中醫(yī)藥,2013,6(4):313-318.
[12] 黃桃芬,盧丹逸,喻芳君,等.HPLC法同時(shí)測定車前草中4種成分的含量[J].中草藥,2017,40(3):645-648.
[13] 林云,江林,蔣健,等.蒲公英的藥理作用研究進(jìn)展[J].中國現(xiàn)代中藥,2011,13(8):42-47.
[14] 張漢慶,肖嫚,劉勇.單味中藥治療骨性關(guān)節(jié)炎研究進(jìn)展[J].中國中醫(yī)骨傷科雜志,2012,20(1):65-67.
[15] 吳劍,鮑同柱,肖長義,等.梔子對兔膝骨關(guān)節(jié)炎模型關(guān)節(jié)軟骨病理改變及IL-1 β表達(dá)的影響[J].第二軍醫(yī)大學(xué)學(xué)報(bào),2009,30(3):329-331.
[16] 辛衛(wèi)云,苗明三.澤蘭的化學(xué)、藥理及臨床應(yīng)用[J].中醫(yī)學(xué)報(bào),2015,30(3):418-420.
[17] 楊煬,稅丕先,陳滟,等.中藥大黃在臨床應(yīng)用中的功效以及對其藥理作用[J].基因組學(xué)與應(yīng)用生物學(xué),2017,36(3):1226-1231.
[18] 陳燕文,胡晶紅,李佳,等.金銀花多糖提取,精制方法和藥理活性綜述[J].遼寧中醫(yī)藥大學(xué)學(xué)報(bào),2017,19(1):155-159.
[19] 王瑩,褚揚(yáng),李偉,等.三七中皂苷成分及其藥理作用的研究進(jìn)展[J].中草藥,2015,46(9):1381-1392.
[20] 張軒,周斌,路慧麗.草烏甲素的藥理作用機(jī)制及臨床應(yīng)用研究進(jìn)展[J].慢性病學(xué)雜志,2016,17(11):1210-1213.
[21] 蔡卓亞,周自桂,李萍,等.伸筋草化學(xué)成分及藥理作用研究進(jìn)展[J].中草藥,2015,46(2):297-304.
[22] 李瑞龍,張強(qiáng),楊劉柱,等.盤龍七片治療急性腰背部軟組織損傷31例[J].中國中醫(yī)骨傷科雜志,2017,25(4):75-76.

相似文獻(xiàn)/References:

[1]鄧偉哲,王宏晶,王宇恒,等.微創(chuàng)針刀鏡治療難治性膝關(guān)節(jié)類風(fēng)濕關(guān)節(jié)炎[J].中醫(yī)正骨,2015,27(11):42.
[2]李楠,李鋒.脛骨平臺骨折的手術(shù)治療進(jìn)展[J].中醫(yī)正骨,2015,27(12):78.
[3]陳利軍,田野,劉文剛,等.非典型膝關(guān)節(jié)外傷后脛骨近端隱匿性骨折的影像診斷[J].中醫(yī)正骨,2015,27(06):26.
[4]湯金城,譚旭儀,成傳德.前外側(cè)切口可吸收螺釘內(nèi)固定治療Hoffa骨折[J].中醫(yī)正骨,2015,27(03):44.
[5]劉道兵,周宇,謝斌,等.關(guān)節(jié)鏡下滑膜切除術(shù)聯(lián)合中藥口服 治療膝關(guān)節(jié)色素沉著絨毛結(jié)節(jié)性滑膜炎[J].中醫(yī)正骨,2013,25(09):34.
[6]張阿雷.關(guān)節(jié)囊外復(fù)位內(nèi)固定治療脛骨平臺骨折[J].中醫(yī)正骨,2016,28(01):54.
[7]李延紅,石耀武,張宏蕾.外敷滑膜膏配合口服四妙丸治療踝關(guān)節(jié)滑膜炎[J].中醫(yī)正骨,2016,28(01):68.
[8]路懷民,譚佳汶,劉蓓,等.運(yùn)動(dòng)療法聯(lián)合中醫(yī)綜合療法治療早期創(chuàng)傷性半月板損傷[J].中醫(yī)正骨,2016,28(03):68.
[9]趙進(jìn)征,吳旭東,黃小剛,等.同種異體肌腱移植治療膝關(guān)節(jié)后外側(cè)角損傷[J].中醫(yī)正骨,2016,28(09):40.
[10]楊小廣,楊喬輝,劉長風(fēng),等.脛骨平臺骨折切開復(fù)位內(nèi)固定術(shù)后膝關(guān)節(jié)功能恢復(fù)的影響因素分析[J].中醫(yī)正骨,2016,28(10):11.
　YANG Xiaoguang,YANG Qiaohui,LIU Changfeng,et al.Analysis of factors influencing knee function recovery after open reduction and internal fixation for treatment of tibial plateau fractures[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2016,28(10):11.
[11]趙新杰,孫實(shí),武愛玲.中醫(yī)藥治療膝關(guān)節(jié)滑膜炎的研究進(jìn)展[J].中醫(yī)正骨,2015,27(08):65.
[12]鄭昱新,詹紅生,莫文,等.滑膜炎顆粒治療膝關(guān)節(jié)滑膜炎濕熱阻絡(luò)證的隨機(jī)、 雙盲、安慰劑對照、多中心臨床研究[J].中醫(yī)正骨,2015,27(12):29.
　ZHENG Yuxin,ZHAN Hongsheng,MO Wen,et al.A randomized,double-blind,placebo-controlled,multicenter,clinical trial of Huamoyan Keli(滑膜炎顆粒)for treatment of gonarthromeningitis with DAMPNESS-HEAT BLOCK COLLATERALS syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(10):29.
[13]赫軍,李冬冬,禹建春,等.口服狐惑蠲痹湯和西藥治療貝赫切特綜合征膝關(guān)節(jié)滑膜炎濕熱瘀阻證[J].中醫(yī)正骨,2019,31(03):51.
[14]彭德強(qiáng),林志東,鐘禮倫,等.全膝關(guān)節(jié)置換術(shù)與關(guān)節(jié)鏡下滑膜切除術(shù)治療晚期膝關(guān)節(jié)色素沉著絨毛結(jié)節(jié)性滑膜炎的Meta分析[J].中醫(yī)正骨,2022,34(01):50.
　PENG Deqiang,LIN Zhidong,ZHONG Lilun,et al.Comparison of total knee arthroplasty and arthroscopic synovectomy for treatment of terminal knee pigmented villonodular synovitis:a meta analysis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2022,34(10):50.

備注/Memo

備注/Memo:
通訊作者:張禮平 E-mail:[email protected]
更新日期/Last Update: 2018-03-10